SCHEMBL15049974

SCHEMBL15049974

Cc1nc2ccc(C(=O)N3CCN(C(=O)OC(C)(C)C)CC3)cn2c1-c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.65
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC4 P56524 1/20 0.46
CKS1B P61024 2/20 0.46
SKP1 P63208 2/20 0.46
SKP2 Q13309 2/20 0.46
GBA1 P04062 2/20 0.45
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
CASP1 P29466 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
CASP7 P55210 1/20 0.44
GPR119 Q8TDV5 3/20 0.44
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
KLK7 P49862 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15071152 0.87 F2RL1 (0.75) F2RL1MEN1KMT2ACKS1BSKP1
SCHEMBL31518 0.85 F2RL1 (0.72) F2RL1MEN1KMT2AGBA1ALDH1A1
SCHEMBL15071100 0.84 F2RL1 (0.77) F2RL1MEN1KMT2AGBA1ALDH1A1
SCHEMBL15050009 0.82 F2RL1 (0.68) F2RL1HPGDPOLBAKT1
SCHEMBL15071143 0.82 F2RL1 (0.74) F2RL1MEN1KMT2AGBA1HPGD
SCHEMBL15071160 0.81 F2RL1 (0.67) F2RL1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL31526 0.81 F2RL1 (0.90) F2RL1MEN1KMT2ACKS1BSKP1
SCHEMBL15071158 0.81 F2RL1 (0.73) F2RL1MEN1KMT2AALDH1A1KDM4E
Hydrochloric Acid SCHEMBL15049976 0.81 F2RL1 (0.67) F2RL1HPGDAKT1
SCHEMBL15074832 0.80 F2RL1 (0.69) F2RL1ALDH1A1KDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617721-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME Neopharm Co., Ltd. (KR) 2013-07-24 EP disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885MEN1 3489/4885KMT2A 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.